USE OF LORAZEPAM FOR PEDIATRIC STATUS EPILEPTICUS (COHORT 2)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项多中心研究的目的是观察劳拉西潘治疗儿童癫痫持续状态的药代动力学。这项研究有两个队列。队列1用于在主动发作时可以登记/服药的患者，而队列2用于将被选择性登记/服药的患者。队列2的排除标准已更改为排除原因不明的肾脏或肝脏疾病超过正常上限的两倍或患者基线值增加两倍的患者。样本量已从60名患者调整为100名患者，研究延长至2006年5月1日。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the multi-center study is to look at the pharmacokinetics of lorazepam for the treatment of pediatric status epileticus. The study has two cohorts. Cohort 1 is for patients that can be enrolled/dosed while actively seizing and cohort 2 is for patients that will be electively enrolled/dosed. The exclusion criterion for cohort 2 has been changed to excluded patients if they have unexplained renal or hepatic disease greater that twice the limit than normal or 2-fold increase of the patients baseline value. The sample size has been adjusted from 60 to 100 patients and the study has been extended until May 1, 2006.